MINERALYS THERAPEUTICS, INC. Operating Cash Flow
MINERALYS THERAPEUTICS, INC. (MLYS) reported Operating Cash Flow of -$72.03 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$32.56M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$39.47M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$37.89M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$28.87M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$142.42M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$166.31M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$81.17M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$29.22M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$32.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$72.03M 10-Q · filed 2026-08-11 | -$109.92M derived: sum of 3 quarters · filed 2026-08-11 | -$138.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$39.47M 10-Q · filed 2026-05-06 | -$77.36M derived: sum of 2 quarters · filed 2026-05-06 | -$106.23M derived: sum of 3 quarters · filed 2026-05-06 | -$136.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$37.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$66.76M derived: sum of 2 quarters · filed 2026-03-12 | -$96.93M derived: sum of 3 quarters · filed 2026-08-11 | -$142.42M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$28.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$59.04M derived: sum of 2 quarters · filed 2026-08-11 | -$104.53M 10-Q · filed 2025-11-10 | -$171.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$30.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$75.66M 10-Q · filed 2026-08-11 | -$142.50M derived: sum of 3 quarters · filed 2026-08-11 | -$192.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$45.49M 10-Q · filed 2026-05-06 | -$112.33M derived: sum of 2 quarters · filed 2026-05-06 | -$162.52M derived: sum of 3 quarters · filed 2026-05-06 | -$192.66M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$66.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$117.03M derived: sum of 2 quarters · filed 2026-03-12 | -$147.18M derived: sum of 3 quarters · filed 2026-03-12 | -$166.31M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$50.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$80.33M derived: sum of 2 quarters · filed 2025-11-10 | -$99.47M 10-Q · filed 2025-11-10 | -$128.45M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$30.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$49.28M 10-Q · filed 2025-08-12 | -$78.27M derived: sum of 3 quarters · filed 2025-08-12 | -$97.30M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$19.14M 10-Q · filed 2025-05-12 | -$48.12M derived: sum of 2 quarters · filed 2025-05-12 | -$67.15M derived: sum of 3 quarters · filed 2025-05-12 | -$87.54M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$28.98M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$48.01M derived: sum of 2 quarters · filed 2025-02-12 | -$68.40M derived: sum of 3 quarters · filed 2025-02-12 | -$81.17M 10-K · filed 2025-02-12 |
| 2023-09-30 | -$19.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$39.42M derived: sum of 2 quarters · filed 2024-11-12 | -$52.19M 10-Q · filed 2024-11-12 | -$62.38M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$20.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$33.16M 10-Q · filed 2024-08-13 | -$43.35M derived: sum of 3 quarters · filed 2024-08-13 | -$50.34M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$12.78M 10-Q · filed 2024-05-09 | -$22.96M derived: sum of 2 quarters · filed 2024-05-09 | -$29.95M derived: sum of 3 quarters · filed 2024-05-09 | -$35.42M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$10.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$17.17M derived: sum of 2 quarters · filed 2024-03-21 | -$22.64M derived: sum of 3 quarters · filed 2024-03-21 | -$29.22M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$6.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$12.46M derived: sum of 2 quarters · filed 2023-11-07 | -$19.04M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$5.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$12.05M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | -$6.58M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |